Treatment of colorectal polyps with imidazoquinoline derivatives
The invention relates to treating colorectal polyps and precancercerous colorectal changes by topical administration of immunomodulating drugs of the imidazoquinoline family, such as imiquimod (1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine), resiquimod (4-amino-α,α-dimethyl-2-ethoxymethyl-1H-imidazo[4,5-c]quinoline-1-ethanol), sotirimod (2-methyl-1-(2-methylpropyl)-1H-imidazo[4,5-c][1,5]naphthyridin-4-amine).
1. A method of treatment of colorectal polyps/polyposis by application of an imidazoquinoline derivative selected from the group consisting of imiquimod, resiquimod and sotirimod.
2. The method of treatment according to claim 1 , wherein the patient is a HIV or immunocompromised patient.
3. The method according to claim 1 , wherein the imidazoquinoline derivative is administered topically, in form of a solution, cream or foam.
4. The method according to claim 1 , wherein the imidazoquinoline derivative is administered 1-7 times per week for several weeks.
5. The method according to claim 4 , wherein the imidazoquinoline derivative is administered 1-5 times per week for several weeks.
6. A method of treatment of precancerous colorectal changes by application of an imidazoquinoline derivative selected from the group consisting of imiquimod, resiquimod and sotirimod.
7. The method according to claim 6 , wherein the imidazoquinoline derivative is administered 1-7 times per week for several weeks.
8. The method according to claim 7 , wherein the imidazoquinoline derivative is administered 1-5 times per week for several weeks.
9. The method of treatment according to claim 6 , wherein the patient is a HIV or immunocompromised patient.
10. The method according to claim 6 , wherein the imidazoquinoline derivative is administered topically, in form of a solution, cream or foam.
11. A method of adjuvant treatment of colorectal polyps/polyposis by application of an imidazoquinoline derivative selected from the group consisting of imiquimod, resiquimod and sotirimod.
12. The method according to claim 11 , wherein the imidazoquinoline derivative is administered 1-7 times per week for several weeks.
13. The method according to claim 12 , wherein the imidazoquinoline derivative is administered 1-5 times per week for several weeks.
14. The method of treatment according to claim 11 , wherein the patient is a HIV or immunocompromised patient.
15. The method according to claim 11 , wherein the imidazoquinoline derivative is administered topically, in form of a solution, cream or foam.